MX2019002019A - Compuestos de beta-amino-isoquinolinil amida. - Google Patents
Compuestos de beta-amino-isoquinolinil amida.Info
- Publication number
- MX2019002019A MX2019002019A MX2019002019A MX2019002019A MX2019002019A MX 2019002019 A MX2019002019 A MX 2019002019A MX 2019002019 A MX2019002019 A MX 2019002019A MX 2019002019 A MX2019002019 A MX 2019002019A MX 2019002019 A MX2019002019 A MX 2019002019A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- beta
- amide compounds
- diseases
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- YZDXFUGIDTUCDA-UHFFFAOYSA-N isoquinoline-1-carboxamide Chemical class C1=CC=C2C(C(=O)N)=NC=CC2=C1 YZDXFUGIDTUCDA-UHFFFAOYSA-N 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000003936 benzamides Chemical class 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377219P | 2016-08-19 | 2016-08-19 | |
| PCT/US2017/025609 WO2018034702A1 (en) | 2016-08-19 | 2017-03-31 | Beta-amino-isoquinolinyl amide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002019A true MX2019002019A (es) | 2019-07-04 |
Family
ID=61191217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002019A MX2019002019A (es) | 2016-08-19 | 2017-03-31 | Compuestos de beta-amino-isoquinolinil amida. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9963432B2 (https=) |
| EP (1) | EP3500251A4 (https=) |
| JP (1) | JP2019529359A (https=) |
| KR (1) | KR20190039587A (https=) |
| CN (1) | CN109640971A (https=) |
| AU (1) | AU2017312712B2 (https=) |
| BR (1) | BR112019003232A2 (https=) |
| CA (1) | CA3033184C (https=) |
| MX (1) | MX2019002019A (https=) |
| WO (1) | WO2018034702A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3828172A1 (en) | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| ES2852377T3 (es) | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| AU2018243687C1 (en) | 2017-03-31 | 2020-12-24 | Alcon Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| CN111936139B (zh) * | 2018-03-30 | 2023-10-13 | 爱瑞制药公司 | 6-氨基异喹啉的单(酸)盐及其用途 |
| JP7437384B2 (ja) * | 2018-08-31 | 2024-02-22 | アエリエ ファーマシューティカルズ インコーポレイテッド | イソキノリンステロイド抱合体およびその使用 |
| CA3112391A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| WO2021001713A1 (en) * | 2019-06-29 | 2021-01-07 | Micro Labs Limited | Process for the preparation of (s)-netarsudil, its salts & polymorphs |
| JP7531379B2 (ja) * | 2019-12-31 | 2024-08-09 | 財團法人工業技術研究院 | βアミノ酸誘導体、これを含むキナーゼ阻害剤および医薬組成物ならびにその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) * | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3828172A1 (en) * | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| ES2852377T3 (es) * | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares |
| US9643927B1 (en) * | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| KR102579582B1 (ko) * | 2015-11-17 | 2023-09-15 | 에어리 파마슈티컬즈, 인코포레이티드 | 키나아제 억제제 및 이의 중간체의 제조 방법 |
-
2017
- 2017-03-31 EP EP17841778.8A patent/EP3500251A4/en not_active Withdrawn
- 2017-03-31 JP JP2019509467A patent/JP2019529359A/ja active Pending
- 2017-03-31 AU AU2017312712A patent/AU2017312712B2/en not_active Ceased
- 2017-03-31 MX MX2019002019A patent/MX2019002019A/es unknown
- 2017-03-31 KR KR1020197007986A patent/KR20190039587A/ko not_active Ceased
- 2017-03-31 WO PCT/US2017/025609 patent/WO2018034702A1/en not_active Ceased
- 2017-03-31 CN CN201780050718.3A patent/CN109640971A/zh active Pending
- 2017-03-31 US US15/476,850 patent/US9963432B2/en active Active
- 2017-03-31 CA CA3033184A patent/CA3033184C/en active Active
- 2017-03-31 BR BR112019003232A patent/BR112019003232A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA3033184A1 (en) | 2018-02-22 |
| WO2018034702A1 (en) | 2018-02-22 |
| AU2017312712A1 (en) | 2019-02-21 |
| CA3033184C (en) | 2024-06-04 |
| CN109640971A (zh) | 2019-04-16 |
| US20180050990A1 (en) | 2018-02-22 |
| AU2017312712B2 (en) | 2019-12-12 |
| EP3500251A4 (en) | 2020-04-08 |
| BR112019003232A2 (pt) | 2019-06-18 |
| JP2019529359A (ja) | 2019-10-17 |
| US9963432B2 (en) | 2018-05-08 |
| KR20190039587A (ko) | 2019-04-12 |
| EP3500251A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011784A (es) | Compuestos de aril ciclopropil-amino-isoquinolinil amida. | |
| MX2019002019A (es) | Compuestos de beta-amino-isoquinolinil amida. | |
| NZ736665A (en) | Heterocyclic amides as kinase inhibitors | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| PH12018501151A1 (en) | Tank-binding kinase inhibitor compounds | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| EA033163B1 (ru) | Ингибиторы глутаминазы | |
| MX2021015102A (es) | Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r). | |
| WO2010011853A3 (en) | Beta-and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | |
| GEAP201914692A (en) | Substituted oxopyridine derivatives | |
| WO2015073587A3 (en) | Synthetic membrane-receiver complexes | |
| JO3316B1 (ar) | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل | |
| PH12018500047B1 (en) | Notch pathway signaling inhibitor compounds | |
| MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX382600B (es) | Forma cristalina de base libre de lorlatinib. | |
| GEP20196961B (en) | 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139 | |
| MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| WO2016176620A8 (en) | Extracellular matrix compositions for the treatment of cancer or immunological diseases | |
| EA033460B1 (ru) | Замещенные [1,2,4]триазольные соединения в качестве фунгицидов | |
| MY188420A (en) | Crystalline forms of (s)-afoxolaner |